Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OraSure OraQuick

This article was originally published in The Gray Sheet

Executive Summary

CDC commits to purchase of 250,000 rapid HIV-1 antibody tests for $2 mil. by Dec. 31 for 50 U.S. locations. Approved in November 2002 and CLIA-waived in January, the test will be used in CDC's HIV testing and prevention initiative. The Bethlehem, Penn. firm donated tests to eight sites for "national HIV testing day" June 27...

You may also be interested in...

OraSure’s MIRIAD results

OraQuick rapid HIV test use in point-of-care labor and delivery settings allows an average 45 minute turn-around time - more than four times faster than the 3.5 hour average needed when the same test is performed in a lab, according to CDC's Maternal Infant Rapid Intervention at Delivery study. Started in November 2001, MIRIAD tested 380 women in Chicago with 100% accuracy, finding and treating three who were HIV positive. OraQuick was approved by FDA in November 2002. CDC's previous purchase of 250,000 of the tests will be finalized in January (1"The Gray Sheet" June 30, 2003, In Brief)...

Dr Reddy's Strengthens Russian OTC Portfolio Through Glenmark Deal

Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from India's Glenmark.

Moderna Files COVID-19 Vaccine After Second Impressive Read-Out

Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts